Trending stocks and marketinsights, made visual.
Data-driven insights into stocks and investing themes. Our visual newsletter takes 5 minutes to read and it’s completely free.
Stories
Stock Ideas
View all ideasTg Therapeutics, Inc.
Tg Therapeutics has shifted to commercial growth, with quarterly revenue rising from $63.5M in 2024Q1 to $240.3M in 2026Q2 and substantial institutional sponsorship.
Biotech TherapeuticsArrowhead Pharmaceuticals, Inc.
Arrowhead has moved into material reported revenue and improving GAAP diluted EPS while trading in an established uptrend with heavy institutional ownership and strong relative strength.
Biotech TherapeuticsExelixis, Inc.
Exelixis pairs steady mid-teens revenue growth and rising GAAP diluted EPS with a confirmed Stage‑2 technical uptrend and strong relative strength within oncology therapeutics.
Biotech TherapeuticsKrystal Biotech, Inc.
Krystal Biotech is a commercial-stage gene therapy company that grew quarterly revenue from $8.6M to $119.2M while delivering consecutive GAAP profits, positioning it as a timely leader in dermatology biotech.
Biotech TherapeuticsBaxter International Inc
Baxter pairs steady mid-single-digit revenue growth with a validated Stage 1→2 breakout, supported by 2.7x base demand and a reclaimed 200-day average, making it a timely leader in medical devices.
Medical Devices & Surgical RoboticsAcadia Pharmaceuticals Inc
Acadia shows steady mid-single- to mid-teens revenue growth, heavy institutional sponsorship, and a validated Stage 1→2 breakout, positioning it as a timely leader in Biotech Therapeutics.
Biotech TherapeuticsMarket insights
View all insightsIAM drives growth acceleration
Docusign’s identity-and-agreement platform adoption is becoming a tangible growth driver rather than a longer-term product narrative. For enterprise software, this supports the view that workflow platforms can reaccelerate growth through adjacent modules and broader deployments.
Read insight →Enterprise deal sizes pick up
The comments point to strengthening large-deal activity across customer segments, functions, and geographies. That is a constructive read-through for enterprise software vendors whose growth depends on expanding strategic deployments rather than only seat additions.
Read insight →Expansion lifts retention quality
A greater contribution from expansion to net retention signals healthier installed-base monetization in enterprise software. The shift matters because it reflects incremental product adoption within existing accounts, not solely improved customer retention.
Read insight →Market insights, made visual.
Get data-driven insights into stocks and investing themes in a free newsletter that takes 5 minutes to read.